Evidence map›Paper›PMID 25534379›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Dual-eligibility status: a marker of vulnerability and cancer-related disparities.

Siran M Koroukian

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status.Journal of health care for the poor and underserved · 2018
    Article
  2. Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017
    Article
  3. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Siran M KoroukianSchool of Medicine; Clinical and Translational Science Collaborative, Case Western Reserve University; and Case Comprehensive Cancer Center, Cleveland, OH skoroukian@case.edu.

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Prevention Research Center for Healthy NeighborhoodsU48DP005030 · DP · CASE WESTERN RESERVE UNIVERSITY · PI BORAWSKI, ELAINE A. · 2014 to 2018
$6.8M
Combination of chronic conditions determining clinical relevance and resource useR21HS023113 · AHRQ · CASE WESTERN RESERVE UNIVERSITY · PI KOROUKIAN, SIRAN M. · 2014 to 2014
$179k
AHRQ HHS R21 HS023113NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1TR000439NCCDPHP CDC HHS 3U48DP005030-01S3
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsFemaleHumansInsurance CoverageMaleMedicareMedicare Part BNeoplasms

Identifiers

PMID25534379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.